Highlights from the 2024 Seattle Cellular Therapy Summit
The 2024 Seattle Cellular Therapy Summit will feature leading experts who will provide a detailed overview of current and emerging strategies for treating lymphoma, myeloma, acute leukemias, and solid tumors with a focus on cellular therapies.
The summit aims to improve participants’ knowledge and skills to apply new clinical data and expert recommendations, enhancing outcomes for patients with blood cancers and exploring future uses of cellular therapy for solid tumors.
Organizing Committee:
- Conference Director – Binay Shah, MD, MHA – Binaytara Foundation
- Conference Co-Chairs – Mazyar Shadman, MD, MPH – Fred Hutchinson Cancer Center and University of Washington, Krish Patel, MD – Swedish Cancer Institute
Target Audience:
- Hematologists/Medical Oncologists
- Oncology fellows
- Oncology nurses
- NPs/PAs
- Oncology pharmacists
Here are some highlights from the event, shared on Social Media:
“The final debate to conclude SCTS24 features Adam Kittai (The Ohio State University Comprehensive Cancer Center – James Cancer Hospital)and Dr. Herbert Eradat (UCLA Health) discussing ‘The Most Promising Immunotherapy Option for Richter Transformation’. ”
“Important talk by Aravind Ramakrishnan on how to enhance access and safety of outpatient CAR-T. Personalizing based on patient and product-specific characteristics is critical. Remote monitoring may help!
Duke Hematologic Malignancies and Cellular Therapy will be piloting a novel multi-vital sign remote monitoring system for CART and bispecific therapies soon!”
“Masterclass with Prof. Mehdi Hamadani on a very controversial topic: are CD19-targeted therapies prior to CD19 CAR T-cell therapy ever a good idea?”
“Fantastic talk by Kelly Paulson on the unique considerations of TILs in advanced melanoma in contrast to CAR T.
Truly a complex multidisciplinary effort, and worth considering early as bridging options are often limited.”
“Enlightening CAR-T Therapy for Autoimmune Diseases talk with Krish Patel (Swedish Cancer Institute) here at session 3 of SCTS24!”
“The success of afami-cel is a cause for celebration in the field of synovial sarcoma:
- Impressive rates and durations of response rates
- Persistence associate with survival, but not related to transduced cells
- Role in adjuvant and other novel T cell therapies are on the horizon.
Great review by Elizabeth Loggers at Binaytara Foundation.”
“Thank you to our co-chairs Mazyar Shadman and Krish Patel, attendees, faculty, volunteers, staff, hotel staff, av team, and everyone involved for another successful Seattle Cellular Therapy Summit! The countdown to 2025 Seattle Cellular Therapy Summit begins.”
Read the post by Mazyar Shadman about the Seattle Cellular Therapy Summit on oncodaily.com
